Investor Presentaiton slide image

Investor Presentaiton

||| Operations and performance Economic-financial results GRI 201-1 Net Revenue In 2021, adjusted net revenue totaled R$ 5,997,4 million, an increase of 35.9% com- pared to 2020. This result is due to an organic growth of 14.2% and acquisitions made during the period. R$ thousand Net Revenue Adjusted net revenue* 2021 6,218,759 5,997,425 2020 4,413,421 4,413,421 Var. 2021/2020 40.9% 35.9% In 2021, the adjusted net revenue of the distribution channel for hospitals and clin- ics totaled R$ 5,109.6 million, an increase of 30.5% compared to 2020. The annual growth is mainly due to the higher sales volume of high-cost drugs and vaccines. The first two quarters saw stronger sales related to Covid-19 and a slowdown in the third and fourth quarters due to the moment of the pandemic and the highly stocked hospitals. In the second half of 2021, there was also a brief resumption of elective procedures, but still below pre-pandemic levels. Organic growth was 12.5% in 2021 compared to 2020. In the distribution channel for hospitals and clinics in 2021, 58.5% of net revenue refers to high-cost drugs, materials (including Cremer) represented by 19.0%, other medicines 15.8%, and vaccines 6.7%. Economic-financial results * Excludes the positive effect of DIFAL (ICMS rate differential) of R$ 17.7 million in 4021 and R$ 221.3 million in 2021. Net revenue per channel % of net revenue 2021 Distribution to hospitals and clinics 5.4% Other materials R$ thousand 2021 2020 Var. 2021/2020 13.6% Manufacture (Cremer) Hospitals and clinics* 5,109,644 3,915,015 30.5% Laboratories 220,260 135,174 62.9% Retail 583,787 315,424 85.1% 15.8% Services 83,734 47,808 75.1% Others Medicine Total 5,997,425 4,413,421 35.9% * Excludes the positive effect of DIFAL (ICMS rate differential) of R$ 221.3 million in 2021. 42 viveo Sustainability Report 2021 6.7% Vaccine and PPE 58.5% High-cost drugs
View entire presentation